1 |
Alsheik A, Mohamedali Z, Jones E, et al (2001). Comparison of the WHO/ISUP classification and cytokeratin expression in predicting the behaviour of low-grade papillary urothelial tumors. Mod Pathol, 14, 267-72.
DOI
|
2 |
Bertz S, Otto W, Denzinger S, et al (2014). Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. European Urol, 65, 218-26.
DOI
|
3 |
Cheng L and Bostwick D (2011). Essentials of Anatomic Pathology. Pub. Springer Science and Business Media, 3rd ed., Ch. 36.
|
4 |
Cina SJ, Lancaster-Weiss KJ, Lecksell K, et al (2001). Correlation of Ki67 and p53 with the new world health organization/international society of urological pathology classification system for urothelial neoplasia. Arch Pathol Lab Med, 125, 646-51.
|
5 |
Eble J, Sauter G, Epstein J and Sesterhenn I (2004). World health organization classification of tumours. pathology and genetics of tumours of the urinary system and male genital organs. Pub. IARC Press Lyon, France, 90-110.
|
6 |
Fletcher C (2013). Diagnostic histopathology of tumors. 4th ed., Pub. Elsevier Saunders, vol. 1, ch. 12, 610-11.
|
7 |
Helpap B, Schmitz-drager B, Hamilton P, et al (2003): Molecular pathology of non-invasive urothelial carcinomas (part 1). Virchows Arch, 442, 309-16.
|
8 |
Krause FS, Feil G, Bichler KH (2000): Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer. Anticancer Res, 20, 5023-8.
|
9 |
Kumar V, Abbas A, Aster J (2015): Robbins and Cotran Pathologic Basis of Disease, 9th ed., Pub. Elseveir Saunders, ch. 21, 1028.
|
10 |
Mallofre C, Castillo M, Morente V, Sole M (2003). Immunohistochemical expression of CK20, p53, and Ki- 67 as objective markers of urothelial dysplasia. Mod Pathol, 16, 187-91.
DOI
|
11 |
McKenney JK, Desai S, Cohen C, Amin MB (2001). Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 Antigens. Am J Surgical Pathol, 25, 1074-8.
DOI
|
12 |
Mehta N, Rathore RS, Pillai BS, et al (2015). Intrinsic tumour factors affecting recurrence in non muscle invasive bladder cancer: a hospital based study from india. Asian Pac J Cancer Prev, 16, 2675-7.
DOI
|
13 |
Mumtaz S, Hashmi AA, Hasan SH, et al (2014). Diagnostic utility of p53 and CK20 immunohistochemical expression grading urothelial malignancies. Int Arch Med, 7, 36.
DOI
|
14 |
Yin H, Leong A (2004). Histologic grading of noninvasive papillary urothelial tumors. validation of the 1998 WHO/ ISUP system by immunophenotyping and Follow-up. Am J Clin Pathol, 121, 679-87.
DOI
|
15 |
Pich A, Chiusa L, Formiconi A, et al (2001). Biological differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol, 25, 1528- 33.
DOI
|
16 |
Tut VM, Braithwaite KL, Angus B, et al (2001). Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer, 84, 270-5.
DOI
|
17 |
Van Oers JM, Wild PJ, Burger M, et al (2007). FGFR3 Mutations and a Normal CK20 Staining Pattern Define Low-Grade Noninvasive Urothelial Bladder Tumours. European Urol, 52, 760-8.
DOI
|
18 |
Zaher A, Sheridan T (2001). Tumor markers in the detection of recurrent transitional cell carcinoma of the bladder. Acta Cytol, 45, 575-81.
DOI
|